JOSEPH BRODERICK, MD
Neurology at Piedmont Ave, Cincinnati, OH
License number
Ohio 35 055278
Category
Psychiatric
Type
Vascular Neurology
License number
Ohio 35 055278
Category
Neurology
Type
Neurology
Address
Address
222 Piedmont Ave SUITE 3100, Cincinnati, OH 45219
Phone
(513) 475-8730
(513) 475-8033 (Fax)
(513) 585-5504
(513) 585-5511 (Fax)
(513) 475-8033 (Fax)
(513) 585-5504
(513) 585-5511 (Fax)
Personal information
See more information about JOSEPH BRODERICK at radaris.comName
Address
Phone
3867 Medina Rd #129, Akron, OH 44333
8231 Woodbine Ave, Cincinnati, OH 45216
7584 Trailwind Dr, Montgomery, OH 45242
7501 Hemrich Dr, Canal Wnchstr, OH 43110
1107 Selma Rd, Springfield, OH 45505
Professional information
Dr. Joseph P Broderick, Cincinnati OH - MD (Doctor of Medicine)
Specialties:
Vascular Neurology
Address:
UC Physicians Neurology
222 Piedmont Ave SUITE 3200, Cincinnati 45219
(513) 475-8730 (Phone)
222 Piedmont Ave SUITE 3200, Cincinnati 45219
(513) 475-8730 (Phone)
Procedures:
EEG (Electroencephalogram)
Conditions:
Alzheimer's Disease, Ataxia, Bell's Palsy, Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma), Carotid Artery Disease, Carpal Tunnel Syndrome, Cerebral Aneurysm, Cerebral Artery Thrombosis, Cerebral Vascular Disease, Cerebrovascular Disease, Cluster Headache, Convulsions, Dementia, Diplopia, Dystonia, Epilepsy, Essential Tremor, Gait Abnormality, Headache, Hydrocephalus, Inflammatory and Toxic Neuropathy, Insomnia, Intervertebral Disc Herniation, Low Back Pain, Meningiomas, Migraine, Multiple Sclerosis (MS), Myoclonus, Optic Neuritis, Parkinsonism, Parkinson's Disease, Peripheral Nerve Disorders, Post-Laminectomy Syndrome, Progressive Supranuclear Palsy (PSP), Pseudotumor Cerebri, Radiculopathy (not Due to Disc Displacement), Restless Legs Syndrome, Sleep Apnea, Spinal Stenosis, Stroke, Syncope, Transient Ischemic Attack (TIA), Tremor, Trigeminal Neuralgia, Vertigo
Certifications:
Neurology, 1988, Vascular Neurology, 2005
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UC Physicians Neurology
222 Piedmont Ave SUITE 3200, Cincinnati 45219
University Hospital
234 Goodman St, Cincinnati 45219
222 Piedmont Ave SUITE 3200, Cincinnati 45219
University Hospital
234 Goodman St, Cincinnati 45219
Education:
Medical School
University Of Cincinnati College Of Medicine
Graduated: 1982
Mayo Clinic Rochester
Mayo Clinic
Graduated: 1987
University Of Cincinnati College Of Medicine
Graduated: 1982
Mayo Clinic Rochester
Mayo Clinic
Graduated: 1987
Joseph P Broderick, Cincinnati OH
Specialties:
Neurologist
Address:
222 Piedmont Ave, Cincinnati, OH 45219
Education:
University of Cincinnati, College of Medicine - Doctor of Medicine
The Mayo Clinic - Fellowship - Cerebrovascular Disease
The Mayo Clinic - Residency - Neurology
The Mayo Clinic - Fellowship - Cerebrovascular Disease
The Mayo Clinic - Residency - Neurology
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology), American Board of Psychiatry and Neurology Sub-certificate in Vascular Neurology (Psychiatry and Neurology)
Joseph Broderick, Cincinnati OH
Specialties:
Neurology, Vascular Neurology
Work:
University of Cincinnati
222 Piedmont Ave, Cincinnati, OH 45219 University Hospital, Inc
234 Goodman St, Cincinnati, OH 45219
222 Piedmont Ave, Cincinnati, OH 45219 University Hospital, Inc
234 Goodman St, Cincinnati, OH 45219
Education:
University of Cincinnati (1982)
Methods For Enhancing The Lysis Of Coagulated Blood With Apolipoprotein E2 Phenotype
US Patent:
7208288, Apr 24, 2007
Filed:
Oct 12, 2001
Appl. No.:
10/398880
Inventors:
Joseph P. Broderick - Cincinnati OH, US
Joseph F. Clark - Cincinnati OH, US
Daniel Woo - Cincinnati OH, US
Joseph F. Clark - Cincinnati OH, US
Daniel Woo - Cincinnati OH, US
International Classification:
C12Q 1/56
US Classification:
435 13, 424 9464, 436 69, 514 2, 514 21, 514822, 53036825
Abstract:
Methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.
Methods For Controlling The Lysis Of Coagulated Blood With Apolipoprotein E4 Theno Type
US Patent:
2004010, May 27, 2004
Filed:
Jul 17, 2003
Appl. No.:
10/398882
Inventors:
Joseph Broderick - Cincinnati OH, US
Joseph Clark - Cincinnati OH, US
Daniel Woo - Cincinnati OH, US
Joseph Clark - Cincinnati OH, US
Daniel Woo - Cincinnati OH, US
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
Methods for inhibiting the lysis of coagulated blood comprise administering to blood a lysis-inhibiting amount of apolipoprotein E4 (Apo E4) or a therapeutic derivative thereof. Methods for reducing the risk of excessive blood clot lysis comprise administering the blood a lysis-inhibiting amount of Apo E4 or a therapeutic derivative thereof. Additional methods for inhibiting the lysis of coagulated blood comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4 wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risk of excessive blood clot lysis comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4, wherein the specific level is based upon the apolipoprotein phenotype of the individual. Additional methods for enhancing the lysis of coagulated blood comprise administering to blood containing a clot lysis agent an Apo E peptide fragment.